The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. (2018)

First Author: Seelig E

Attributed to: Adaptive Clinical Trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1172/jci.insight.99306

PubMed Identifier: 30282826

Publication URI: http://europepmc.org/abstract/MED/30282826

Type: Journal Article/Review

Volume: 3

Parent Publication: JCI insight

Issue: 19

ISSN: 2379-3708